Clinical and laboratory specialists from Children’s Hospital of Philadelphia are hosting a webinar exploring the hospital’s Liquid Biopsy for Neuroblastoma Panel. This cutting-edge molecular test is designed to enhance disease monitoring and treatment decisions. This session will highlight how liquid biopsy can detect tumor heterogeneity and allow identification of precision therapy targets in high-risk neuroblastoma patients; describe how serial liquid biopsies can be used to detect early relapse; and explain critical pre-analytic test variables that affect clinical sensitivity.